J Korean Med Sci.
2018 Jan;33(1):e7. 10.3346/jkms.2018.33.e7.
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
- Affiliations
-
- 1Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea. droij@chonnam.ac.kr
- 2Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun, Korea.
- 3Department of Pathology, Konkuk University Hospital, Seoul, Korea.
- 4Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- 5Department of Pathology, Chonnam National University Medical School, Gwangju, Korea.
- KMID: 2399164
- DOI: http://doi.org/10.3346/jkms.2018.33.e7
Abstract
- Human epidermal growth factor receptor 2 (HER2) mutation in non-small cell lung cancer (NSCLC) is an oncogenic driver that possibly becomes a druggable target to HER2-targeted therapy. The benefit of HER2-targeted therapy is much less defined especially in eastern populations. We provide evidence of clinical benefit of afatinib in a 50-year-old Asian woman with HER2-mutant NSCLC who previously failed cytotoxic chemotherapy and gefitinib treatment. Next-generation sequencing of the tumor tissue revealed a HER2 exon 20 mutation (c.2437A > G), which has never been reported. The patient was treated with afatinib for more than four months. She showed rapid radiologic response within a month, and maintained stable state until the last dose of afatinib.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
- Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
- Afatinib Mediates Autophagic Degradation of ORAI1, STIM1, and SERCA2, Which Inhibits Proliferation of Non–Small Cell Lung Cancer Cells
- Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
- Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
